Pharmaceuticals, Biotechnology and Life Sciences
European Commission has approved Novartis’s Votubia (everolimus) dispersible tablets as an adjunctive treatment for patients aged two years and older whose…
European Commission (EC) has granted Marketing Authorization of ONIVYDE, also known as nal-IRI or MM-398, for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine-based therapy.
European Commission has approved Switzerland-based Novartis’ Entresto tablets for treating adult patients with symptomatic chronic heart failure with reduced ejection fraction.
The European Commission (EC) has approved Novartis’ Cosentyx (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS.
Vectura’s partner on the VR876 programme has achieved an important development milestone in Europe, which triggered a cash milestone payment of €5m (circa. £3.6m) to Vectura.
The European Commission has approved the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) for the treatment of adult patients with…